Prescription drug · BLA
Blenrep (Belantamab mafodotin) NDC 0173-0913
Belantamab mafodotin 50 mg/mL · Injection, Powder, For solution · Intravenous · GlaxoSmithKline LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0173-0913-01 | 00173091301 | 1 VIAL in 1 CARTON (0173-0913-01) / 1.4 mL in 1 VIALMarketed from Oct 23, 2025 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Blenrep
- Generic name (nonproprietary)
- belantamab mafodotin
- Active ingredients
- Belantamab mafodotin — 50 mg/mL
- Dosage form
- Injection, Powder, For solution
- Route
- Intravenous
- Labeler
- GlaxoSmithKline LLCNDC labeler code 0173
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761440
- Marketing start
- Listing expires
- Identifiers
- Product ID 0173-0913_aef7c34c-fef8-407c-99c0-a68aded53c60SPL ID aef7c34c-fef8-407c-99c0-a68aded53c60SPL set ID aef7c34c-fef8-407c-99c0-a68aded53c60RxCUI 2725585, 2725587UNII DB1041CXDG
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N400173091301followed by a unit qualifier and the quantityPackage 00173-0913-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. BLENREP, a B‑cell maturation antigen (BCMA)‑directed antibody and microtubule inhibitor conjugate, is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 0173-0913
- What is NDC 0173-0913?
- 0173-0913 is the product NDC for Blenrep (belantamab mafodotin), Belantamab mafodotin 50 mg/mL injection, powder, for solution, listed with the FDA by GlaxoSmithKline LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Blenrep (Belantamab mafodotin).
- What is the active ingredient?
- Belantamab mafodotin.
- Who is the labeler?
- GlaxoSmithKline LLC, NDC labeler code 0173. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Blenrep?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.